Loading clinical trials...

Cardiac Safety of Indacaterol | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Cardiac Safety of Indacaterol

A Randomized, Multiple-dose, Placebo- and Positive-controlled Parallel Group Study to Evaluate the Effects of Indacaterol on Cardiac Safety in Healthy Subjects

NCT01263808•Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy, non-smoking
•Body mass index (BMI) 18.5-32 kg/m2
•Body weight at least 50 kg

Exclusion Criteria

•Recent/concurrent use of concomitant medications (except acetaminophen)
•Recent participation in other clinical trials
•Recent donation or loss of blood
•History/presence of a range of medical conditions, including electrocardiographic (ECG) abnormalities, diabetes mellitus, hyperthyroidism and impaired renal function

Locations (1)

Novartis investigative site

Miami, Florida, United States

Key Dates

Start Date

April 1, 2008

Primary Completion Date

August 1, 2008

Last Updated

December 21, 2010

Enrollment

404

ACTUAL participants

Conditions

Healthy VolunteersChronic Obstructive Pulmonary Disease

Interventions

Indacaterol 150 µg

DRUG

Indacaterol 300 µg

DRUG

Indacaterol 600 µg

DRUG

Placebo

DRUG

Placebo/moxifloxacin

DRUG

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGPHASE1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06342713

Healthy ParticipantsHealthy Subjects+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 21, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cardiac Safety of Indacaterol

Inclusion Criteria

Exclusion Criteria

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

cfMSC Stem Cell Therapy Targeting COPD

A Study of ENX-104 in Healthy Participants

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension